NO20031270L - Imidazolderivater som Raf-kinaseinhibitorer - Google Patents

Imidazolderivater som Raf-kinaseinhibitorer

Info

Publication number
NO20031270L
NO20031270L NO20031270A NO20031270A NO20031270L NO 20031270 L NO20031270 L NO 20031270L NO 20031270 A NO20031270 A NO 20031270A NO 20031270 A NO20031270 A NO 20031270A NO 20031270 L NO20031270 L NO 20031270L
Authority
NO
Norway
Prior art keywords
kinase inhibitors
raf kinase
imidazole derivatives
migraine
pain
Prior art date
Application number
NO20031270A
Other languages
English (en)
Other versions
NO20031270D0 (no
Inventor
David Kenneth Dean
Andrew Kenneth Takle
David Matthew Wilson
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0023196A external-priority patent/GB0023196D0/en
Priority claimed from GB0023208A external-priority patent/GB0023208D0/en
Priority claimed from GB0023197A external-priority patent/GB0023197D0/en
Priority claimed from GB0023193A external-priority patent/GB0023193D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO20031270D0 publication Critical patent/NO20031270D0/no
Publication of NO20031270L publication Critical patent/NO20031270L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20031270A 2000-09-21 2003-03-19 Imidazolderivater som Raf-kinaseinhibitorer NO20031270L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0023196A GB0023196D0 (en) 2000-09-21 2000-09-21 Compouds
GB0023208A GB0023208D0 (en) 2000-09-21 2000-09-21 Compounds
GB0023197A GB0023197D0 (en) 2000-09-21 2000-09-21 Compounds
GB0023193A GB0023193D0 (en) 2000-09-21 2000-09-21 Compounds
PCT/GB2001/004195 WO2002024680A1 (en) 2000-09-21 2001-09-19 Imidazole derivatives as raf kinase inhibitors

Publications (2)

Publication Number Publication Date
NO20031270D0 NO20031270D0 (no) 2003-03-19
NO20031270L true NO20031270L (no) 2003-05-19

Family

ID=27447885

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031270A NO20031270L (no) 2000-09-21 2003-03-19 Imidazolderivater som Raf-kinaseinhibitorer

Country Status (21)

Country Link
US (2) US7199137B2 (no)
EP (1) EP1318992B1 (no)
JP (1) JP2004509882A (no)
KR (1) KR20030030027A (no)
CN (1) CN1471523A (no)
AT (1) ATE300529T1 (no)
AU (1) AU2001287901A1 (no)
BR (1) BR0114023A (no)
CA (1) CA2423154A1 (no)
CY (1) CY1105251T1 (no)
CZ (1) CZ2003793A3 (no)
DE (1) DE60112312T2 (no)
DK (1) DK1318992T3 (no)
ES (1) ES2242767T3 (no)
HU (1) HUP0301181A2 (no)
IL (1) IL154949A0 (no)
MX (1) MXPA03002449A (no)
NO (1) NO20031270L (no)
PL (1) PL361397A1 (no)
PT (1) PT1318992E (no)
WO (1) WO2002024680A1 (no)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200201364T2 (tr) * 1999-11-22 2002-10-21 Smithkline Beecham P. L. C. Yeni bileşikler.
ES2218391T3 (es) * 2000-03-06 2004-11-16 Smithkline Beecham Plc Derivados de imidazol como inhibidores de raf-cinasa.
ES2289004T3 (es) * 2000-11-20 2008-02-01 Smithkline Beecham Corporation Nuevos compuestos.
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
US7446106B2 (en) 2001-09-05 2008-11-04 Smithkline Beecham Plc Pyridylfurans and pyrroles as Raf kinase inhibitors
GB0121490D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Ciompounds
US20040192689A1 (en) * 2001-09-05 2004-09-30 Dean David Kenneth Heterocycle-carboxamide derivatives as raf kinase inhibitors
GB0121488D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
AU2003221684A1 (en) * 2002-04-08 2003-10-27 Smithkline Beecham Corporation Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
AU2003264018A1 (en) 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
IL166510A0 (en) 2002-08-09 2006-01-15 Nps Pharma Inc 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5
MXPA05001592A (es) * 2002-08-09 2005-05-05 Astrazeneca Ab Oxadiazoles como moduladores de receptor-5 de glutamato metabotropico.
AU2003257329C1 (en) 2002-08-19 2010-07-22 Lorus Therapeutics Inc. 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
US20050250837A1 (en) * 2002-10-18 2005-11-10 D Mello Santosh R Use of C-Raf inhibitors for the treatment of neurodegenerative diseases
US20090264494A1 (en) * 2002-10-18 2009-10-22 Board Of Regents, The University Of Texas System Use of neuroprotective 3-substituted indolone compositions
JP2006525962A (ja) * 2003-04-14 2006-11-16 ノバルティス アクチエンゲゼルシャフト 増殖性疾患を処置するためのおよび増殖性疾患の処置の効果をモニタリングするための方法
US7569593B2 (en) * 2003-10-02 2009-08-04 Irm Llc Compounds and compositions as protein kinase inhibitors
US8969372B2 (en) 2003-11-14 2015-03-03 Aptose Boisciences Inc. Aryl imidazoles and their use as anti-cancer agents
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
AU2006250809B2 (en) 2005-05-25 2011-05-12 Lorus Therapeutics Inc. 2-indolyl imidazo(4,5-D)phenanthroline derivatives and their use in the treatment of cancer
CA2814598A1 (en) 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
CA2668961A1 (en) * 2006-11-08 2008-05-15 The Regents Of The University Of Michigan Spink1 as a prostate cancer marker and uses thereof
BRPI0806365B8 (pt) 2007-02-06 2021-05-25 Lixte Biotechnology Holdings Inc composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
ES2376509T3 (es) * 2007-07-06 2012-03-14 The Regents Of The University Of Michigan Reordenamientos de genes mipol 1-etv1.
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
EP2181987B9 (en) 2007-08-23 2014-09-03 Takeda Pharmaceutical Company Limited 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer
US8344135B2 (en) 2007-08-29 2013-01-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JP5730575B2 (ja) * 2007-10-01 2015-06-10 リクスト・バイオテクノロジー，インコーポレイテッド Ｈｄａｃ阻害剤
WO2010014220A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
CN102712953A (zh) * 2009-09-17 2012-10-03 密歇根大学董事会 前列腺癌中的复发性基因融合物
WO2011085269A1 (en) * 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Raf kinase inhibitors
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
WO2013022766A1 (en) * 2011-08-05 2013-02-14 Flynn Gary A Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
CN103159735B (zh) * 2011-12-10 2015-12-09 通化济达医药有限公司 取代的咪唑激酶抑制剂
CN103159736B (zh) * 2011-12-10 2015-05-13 通化济达医药有限公司 取代的吡唑激酶抑制剂
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
US20150232452A1 (en) * 2012-09-19 2015-08-20 Ruga Corporation Novel raf kinase inhibitors
WO2014153464A2 (en) 2013-03-20 2014-09-25 Lorus Therapeutics Inc. 2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
KR20160004299A (ko) 2013-04-09 2016-01-12 릭스트 바이오테크놀로지, 인코포레이티드 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
ES2775579T3 (es) 2013-10-04 2020-07-27 Aptose Biosciences Inc Composiciones para el tratamiento del cáncer
EP4324477A3 (en) 2016-12-08 2024-05-22 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
CN111417395A (zh) 2017-10-30 2020-07-14 艾普托斯生物科学公司 用于治疗癌症的芳基咪唑
CN108484587A (zh) * 2018-06-03 2018-09-04 刘思良 一种Raf激酶抑制剂及其在癌症治疗中的应用
WO2022249192A1 (en) * 2021-05-27 2022-12-01 Ramot At Tel-Aviv University Ltd. Broad-spectrum metastasis suppressing compounds and therapeutic uses thereof in human tumors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236917A (en) * 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
WO1995003297A1 (en) * 1993-07-21 1995-02-02 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
WO1996041645A1 (en) 1995-06-12 1996-12-27 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
CA2250232A1 (en) 1996-04-03 1997-10-09 Allen I. Oliff A method of treating cancer
EP0906307B1 (en) * 1996-06-10 2005-04-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
JP2000511558A (ja) 1996-06-21 2000-09-05 アラーガン・セイルズ・インコーポレイテッド レチノイドおよび／またはレチノイド拮抗剤様生物学的活性を有する置換テトラヒドロナフタレンおよびジヒドロナフタレン誘導体
CZ298022B6 (cs) 1996-10-15 2007-05-30 G. D. Searle & Co. Použití inhibitoru cyklooxygenázy-2 pro výrobu léciva pro lécení a prevenci neoplazie
CZ146999A3 (cs) 1996-10-30 1999-09-15 Schering Corporation Piperazinové deriváty jako antagonisté neurokininu
DE69821132T2 (de) 1997-10-27 2004-10-21 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
HUP0004947A2 (hu) 1997-11-14 2002-03-28 Sankyo Co., Ltd. Piridilpirrol-származékok
WO2000006124A2 (en) 1998-07-30 2000-02-10 Point Biomedical Corporation A novel excipient for the lyophilization of aqueous suspensions of microparticles

Also Published As

Publication number Publication date
CZ2003793A3 (cs) 2004-04-14
EP1318992B1 (en) 2005-07-27
PL361397A1 (en) 2004-10-04
CY1105251T1 (el) 2010-03-03
NO20031270D0 (no) 2003-03-19
ATE300529T1 (de) 2005-08-15
DK1318992T3 (da) 2005-11-21
KR20030030027A (ko) 2003-04-16
MXPA03002449A (es) 2003-06-19
AU2001287901A1 (en) 2002-04-02
ES2242767T3 (es) 2005-11-16
US7199137B2 (en) 2007-04-03
BR0114023A (pt) 2004-02-03
HUP0301181A2 (en) 2007-02-28
CA2423154A1 (en) 2002-03-28
US20040038964A1 (en) 2004-02-26
IL154949A0 (en) 2003-10-31
EP1318992A1 (en) 2003-06-18
DE60112312D1 (de) 2005-09-01
US20070135433A1 (en) 2007-06-14
PT1318992E (pt) 2005-11-30
JP2004509882A (ja) 2004-04-02
WO2002024680A1 (en) 2002-03-28
CN1471523A (zh) 2004-01-28
DE60112312T2 (de) 2005-12-29

Similar Documents

Publication Publication Date Title
DK1318992T3 (da) Imidazolderivater som Raf-kinaseinhibitorer
DK1423384T3 (da) Pyridinderivater som Raf kinaseinhibitorer
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
DE50310516D1 (de) Fredericamycin-derivate
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
NO20091618L (no) Bicykliske triazoler som proteinkinasemodulatorer
WO2003080582A3 (de) Fredericamycin-derivate
DE60319158D1 (de) Pyrazoloisoquinolinenderivaten als kinase inhibitoren
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
ZA200700481B (en) N-(1-(1-beznyl-4-pheynl-1H-imidazol-2-yl)-2,2-dymenthylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer
ATE484508T1 (de) Furylverbindungen
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
PT1325011E (pt) Metodos e compostos para tratamento de doencas proliferativas
ATE468341T1 (de) Thienopyrazole
DE60328603D1 (de) Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
GB0121494D0 (en) Compounds
BRPI0415390A (pt) compostos de pirazinona substituìda para o tratamento da inflamação
TR200002203T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
IT1306165B1 (it) Impiego di inibitori della sostanza p per il trattamento degliadenocarcinomi.
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer
UA90254C2 (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ
TW200602023A (en) Monocyclic heterocycles as kinase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application